A practical reference on GHRH receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-07. Anything still debated is marked as such rather than presented as settled.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
The Department of Mines and Petroleum was a department of the Government of Western Australia until it was superseded by the Department of Mines, Industry Regulation & Safety on 1 July 2017. The department was formed on 1 January 2009, out of the former Department of Industry & Resources and Department of Consumer & Employment Protection, which were split into three new departments, the Department of Mines & Petroleum, the Department of State Development and the Department of Commerce. Its focus is the resources sector, maintaining a mining and petroleum regulatory role and incorporating the resources safety responsibilities from the former Department of Consumer & Employment Protection. It also oversees the Geological Survey of Western Australia. The department operates the Mindex website, a continuously updated database containing information on mines, mineral deposits and prospects in Western Australia.
There are no widely accepted functions for the resulting truncated RNA transcripts. However, a study in 1981 found evidence that there was a relationship between the number of abortive transcripts produced and the time until long RNA strands are successfully produced. When RNA polymerase undergoes abortive transcription in the presence of ATP, UTP, and GTP, a complex is formed that has a much lower capacity for abortive recycling and a much higher rate of synthesis of the full-length RNA transcript. A study in 2010 found evidence that these truncated transcripts inhibit termination of RNA synthesis by a RNA hairpin-dependent intrinsic terminator. Oligonucleotide Eukaryotic transcription Bacterial transcription
The only stable yttrium isotope, 89Y, will be found with yield somewhat less than 1% in a fission product mixture which has been allowed to age for months or years, as the next-longest lived yttrium isotopes have half-lives of only 107 days (88Y) or 59 days (91Y). However, a small amount of yttrium-90 will be found in secular equilibrium with its parent strontium-90 unless the two elements are separated from each other. 90Sr decays into 90Y which is a beta emitter with a half-life of 2.67 days. 90Y is sometimes used for medical purposes and can be obtained either by the neutron activation of stable 89Y or by using a device similar to a technetium cow. As the half-lives of the unstable yttrium isotopes are low (88Y being the longest at 106 days), yttrium extracted from strontium-free moderately aged spent fuel has negligible radioactivity. However, the strong gamma emitter 90Y will be present as long as its parent nuclide 90Sr is. Should a nonradioactive sample of yttrium be desired, care must be taken to remove all traces of strontium and sufficient time to let the short lived Y-90 (64 hours half-life) decay must be allowed before the product can be used.
Sources: en.wikipedia.org
== Clinical features == The disease caused by infection with this parasite is known as rangeliosis. In Brazil it is also known as nambi-uvú (bleeding ears), peste de sangue (bleeding plague) and febre amarela dos cães (yellow fever of dogs).
For services to Science. Roberta Diane Turley, lately Private Secretary, Nuclear Electric plc. For services to the Electricity Industry. Jean Venables, Director, Venables Consultancy Services. For services to Civil Engineering. Beryl Vickerton, Clerk, Atwick Parish Council. For services to Local Government. Christina Mary Waddell. For services to Victim Support and to Carers of Disabled People in Stirling. John Hill Waddell, lately Her Majesty's Inspector of Immigration for Scotland and Northern Ireland, Home Office. Peter Waddington. For services to the community in Downton, Wiltshire. Ann Cunningham Wagstaff, Executive Officer, Ministry of Defence. Geoffrey James George Wakeling, Senior Engineer, Leicestershire County Council. For services to Highways Improvement. Graham Basil Walker, Coxswain/Mechanic, Wells Lifeboat, Norfolk. For services to the Royal National Lifeboat Institution. Mary Walker, Chairman, General Committee of the Christie Hospital and Holt Radium Institute Women's Trust Fund. For charitable services. Nancy Hamilton Walker, Editor, Kinross Newsletter. For services to the community in Kinross-shire. Patricia Ann Walker, Valuation Referencer, Board of Inland Revenue. Sheila Mary Walker. For charitable services. Freda Inez Walley. For services to the community, particularly Prisoner Welfare, in Walsall. Valerie Ann Wallis, Vice-Chairman, Young Men's Christian Association. For services to Young People in Kent. John Wardrobe. For services to Association Football for Young People.
In 2017, he was given the additional charge of Skill Development. As Labour Minister, Lad publicly supported women's participation in night-shift employment and opposed recommendations that women should be restricted from night work because of domestic responsibilities.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.